59mon MSN
Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback